The purpose of this study is to test the how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future.

We will be administering three drugs. Dutasteride is FDA approved to treat prostate enlargement. Lupron is approved for treatment of prostate cancer. Testosterone is approved for treatment of testicular insufficiency. They are being used in this study for "off-label" research purposes. This study will allow us to find out the effect of food on two formulations of testosterone taken by mouth, and the relative effect of food on testosterone absorption.

Information from this study may be useful in treatment of men with low testosterone levels and the development of a male hormonal contraceptive.

Condition	Intervention	Phase
Contraception Hypogonadism	Drug: Oral Testosterone	Phase II

Further Study Details: 

Primary Outcomes: The primary biological end points in this trial will be elevations in serum T while monitoring for any adverse changes in liver function or general health.
Expected Total Enrollment:  18

The drug Lupron, will temporarily turn off the body’s production of testosterone after two weeks. At that point, we will administer testosterone by mouth on six days in the next two weeks to see how much is absorbed and present in the bloodstream after administration. The day Lupron is given, and for 24 days after that, subjects will take the second medication, Dutasteride, which alters testosterone breakdown in the body. Fifteen days after the Lupron shot, subjects will take the first formulation of testosterone by mouth and undergo blood draws to see how much of this testosterone makes it into the blood stream and how long it lasts. The next day(Day 2) subjects will take a larger dose of testosterone and undergo blood draws. On study day 3, subjects will again take the larger dose of testosterone, this time with a meal and undergo blood draws. During the 2nd week of the study, subjects will repeat the testosterone doses, with a 2nd formulation of testosterone. The first two doses of testosterone each week will be taken on an empty stomach, while the third will be taken with breakfast. Please note that six study days: 1,2,3,8,9 and 10 will require repeated blood draws over a 12 hour period.

Ages Eligible for Study:  18 Years   -   50 Years,  Genders Eligible for Study:  Male

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

Male 18-50 yrs old

in good general health based on normal screening evaluation (consisting of medical history, physical exam, normal serum chemistry, hematology, and baseline hormone levels)

Exclusion Criteria:

poor general health, with abnormal blood results at screening

a known history of alcohol or drug abuse

Participation in a long-term male contraceptive study within three months of screening.

Please refer to this study by ClinicalTrials.gov identifier  NCT00161421

Kymberley Anable      206-616-0482    kymmkatt@u.washington.edu
Volunteer Line (Seattle, WA)      206-616-1818 

Washington
      University of Washington, Seattle,  Washington,  98195,  United States; Recruiting

Study chairs or principal investigators

William J Bremner, MD, PhD,  Principal Investigator,  University of Washington   

Study ID Numbers:  04-4115-D
Last Updated:  September 11, 2005
Record first received:  September 8, 2005
ClinicalTrials.gov Identifier:  NCT00161421
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13